The 27 Lead Drug Molecules Acquired from Biotechs in 2021
Our team conducted a review of all the biotech acquisitions of 2021 and distilled it down to the acquisitions…
6 mins read
Molecules of the MOnth
molecule of the day
PF-06882961 – September
Popular Content
DRUG DISCOVERY RESOURCES
- Drug Discovery Resources
- Drug Discovery Posters and Cheat Sheets
- Drug Discovery IPOs and Industry Reviews
- Lists of Approved Drugs
- Classics in Drug Discovery
- Drug Discovery Books
- Drug Discovery Conferences
- What is a Drug Hunter?
- Topliss Tree and Topliss Scheme Posters
- PK Reference Table / Cheat Sheet
- Pd-Couplings Table / Cheat Sheet
- Phase I Drug Metabolism
- Approved Covalent Drug Mechanisms
- Why LogD Matters / LogD Poster
- Types of Kinase Inhibitors
- Unusual Molecular Interactions from the PDB
- Bioactivation of Structural Alerts
- The Square Cube Law
- Don’t Work on Things That Don’t Work
- What is a Biologic Drug Anyway?
- Managing Liver Injury (DILI) Risk
- Where Do Hits Come From?
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen
- Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others
RECENT PREMIUM SLIDE DECK
DRUG DISCOVERY CONFERENCES AND EVENTS
DRUG DISCOVERY Careers
Associate Director / Director
South San Francisco, CA
Septerna
Senior Director
Cambridge, MA
Tango Therapeutics
Director of DMPK
Great Abington, UK
Amphista Therapeutics
hall of fame: past molecules of the month
Check out previous entries below.
2022
2021
2020
past molecules of the year nominees
Check out previous nominees below.
past molecules of the year
Check out previous selections below.
Our Sponsors
Sinocompound
Sinocompound is a global provider of advanced homogeneous catalysts and ligands and specialist services for a range of pharmaceutical and fine chemical applications. We have expertise ranging from R&D all the way through to scale-up and commercial manufacturing. Our proven process is built around our next generation technologies, flexibility, and speed-of-response ensuring delivery at the scale required for your project. Our success is due to our dedication to listening to customers and developing bespoke solutions that help the industry overcome its challenges and customers accelerate their route to market. In order to facilitate this process further, we also offer catalyst screening and custom synthesis services.
Find out how to scale your product when limited by catalyst availability here.
Featured Reviewers
Testimonials
-
“Drug Hunter has a great overview of what is happening in our field, saves time on scouring through news feeds, literature and irrelevant stuff that comes up. It is a tool specifically for people like me to weed out the noise. Big time saver.”
Cyril Bucher
Drug Discovery Scientist, Denali Therapeutics / Publicly Listed Biotech
-
“I look forward to reading the summaries that come out every month. It helps me keep up to date on what’s going on in the industry.”
Hilary Beck
Senior Director, Head of Medicinal Chemistry, Eikon Therapeutics / VC-Backed Biotech
-
“When I need to find information, I know that I can find it on Drug Hunter. This is what was always missing in our field. I’ve been designing drugs for years and the most frustrating part is learning on your own. You may need to go through hundreds of articles to find the information you need. Drug Hunter cuts down on a lot of this!”
Berenger Biannic
Associate Director, Drug Discovery, Essa Pharma / Publicly Listed Biotech
-
“Drug Hunter helps keep me up to date with the scientific literature and saves me so much valuable time. Please continue the excellent work!”
Vincent Guerlavais
Senior Director of Medicinal Chemistry, Protagonist Therapeutics / Publicly Listed Biotech
-
“The thing I like most about it is the concise, to-the-point presentation of the relevant information in an easily digestible format, that is readily accessible to all, from experienced drug hunters to scientists who are just starting their careers. The time-savings achieved by using Drug Hunter are another major selling point. Keep up the good work, folks!”
David Barrett
Executive Director, Science and Strategy Advisor, Astellas Pharma
-
“I like Drug Hunter! I realize that the team puts so much time and effort into this work and it is not easy work. It is a key opinion leader in the industry. I want Drug Hunter to go on forever. It’s really good!”
Mark Baik
Founder and CEO, Arum Therapeutics / Privately Held Biotech
-
“Drug Hunter is really good at summarizing all of the key information. It really helps me understand and digest things!”
Yuebiao Zhou
Senior Scientist, Drug Discovery, Genentech
-
“The cheat sheets that are published are great. Having a centralized resource of those is super helpful. When I recently onboarded a new team member, I taught her about Topliss trees using Drug Hunter. I am way more on top of the med. chem literature because of Drug Hunter!”
Benjamin Horning
Senior Scientist, Medicinal Chemistry, Vividion Therapeutics
-
“I don’t know of anything similar to this. It’s great that I can visit the site and get a pointer to recent important papers in the field. With the article annotations, I also get a perspective I may not get just by reading papers myself.”
Matthew Robinson
Computational Chemist, PostEra
-
“I know I can find new information, targets, and compounds on Drug Hunter each month, which has been really helpful. It’s a good website to see the latest news in drug discovery!”
TJ Bing
Senior Group Leader, Pharmaron
-
“Drug Hunters highly informed, relevant science, category-leading approach is time saving, cost saving and importantly a consistent source of inspiration for new Product Development programs. More like this please Drug Hunter!”
Trevor Brett
Director of Business Development, Pharmalex
-
“I like that Drug Hunter shows condensed information about what is at the forefront of medicinal chemistry at the moment. The molecules are great, I would otherwise have to sift through a lot of articles to find these drugs. I am very satisfied with Drug Hunter.”
Grant Shibuya
Medicinal Chemist, RAPT Therapeutics / Publicly Listed Biotech
-
As both an academic and (most recently) an industrial medicinal chemist, the Drug Hunter resources have been very helpful so far. I’ve passed along several of the excellent primer/cheat sheets to my own students, and the lists of CROs and investors have been helpful for company building. Of course, the Molecules of the Month, and the deep science and strategy behind their structures shared in…
Chris Dockendorff
Academic, Industrial Chemist
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen |Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others